This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Extensive Neupro (R) (rotigotine transdermal system) data to be presented at the 62nd American Academy of Neurology Meet

April 8th, 2010

Extensive new data on rotigotine will be presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada between April 10th and 17th, 2010.

At a series of oral and poster presentations, leading international investigators will report the latest data on rotigotine in all stages of Parkinson's disease and in moderate to severe Restless Legs Syndrome (RLS).

Oral presentations

SP710 (5 year) Long-term Safety and Efficacy of Rotigotine in Patients with Idiopathic RLS: 5-year Results from a Prospective Multinational Open-label Follow-up Study

Högl B, Trenkwalder C, Garcia-Borreguero D, Kohnen R, Poewe W, Stiasny-Kolster K, Bauer L, Fichtner A, Schollmayer E, Oertel W for the SP710 study group

The presentation will report on the final 5-year analysis from a prospective follow-up of a placebo-controlled phase II trial with rotigotine in patients with moderate to severe RLS.

Date: Tuesday, April 13, 2010

Scientific Session #: S04.006: Sleep Disorders

Authors present: 3:00 PM EDT

Place: Constitution Hall 107

RECOVER: Effect of Rotigotine on Non-motor Symptoms in Subjects with Idiopathic Parkinson's Disease

Chaudhuri KR, Rudzinska M, Kies B, Fine J, Hill DL, Anderson T, Surmann E, Whitesides J, Boroojerdi B and Trenkwalder C, on behalf of the RECOVER study group

The presentation will report on the effect of rotigotine on non-motor symptoms of Parkinson's disease, such as sleep, mood and cognition.

Date: Wednesday, April 14, 2010

Scientific Session #: S23.006: Movement Disorders: Parkinson's Disease/Non-Motor

Authors present: 3:15 PM EDT

Place: Room 718AB

Poster presentations

RECOVER: Effect of Rotigotine on Sleep Quality and Control of Early Morning Motor Function in Subjects with Idiopathic Parkinson's Disease

The presentation will report on the effects of rotigotine on movement and sleep problems in people with Parkinson's disease.

Kies B, Chaudhuri KR, Anderson T, Fine J, Hill DL, Rudzinska M, Surmann E, Whitesides J, Boroojerdi B, Trenkwalder C on behalf of the RECOVER Study Group

Date: Tuesday, April 13, 2010

Poster #: P01.240: Movement Disorders: Parkinson's Disease/Non-Motor Symptoms

Authors present: 7:30 AM EDT

Place: Room 808

Long-Term Treatment of Advanced Parkinson's Disease With Rotigotine

LeWitt P, Boroojerdi B, Poewe W, on behalf of the SP516 and SP715 study groups

The presentation will report on the long-term efficacy (over 4-6 years) of rotigotine in people with advanced Parkinson's disease.

Date: Wednesday, April 14, 2010

Poster #: P04.131: Movement Disorders: Parkinson's Disease: Treatment

Authors present: 6:00 PM EDT

Place: Room 808

Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease

Watts R, Boroojerdi B, Jankovic J, on behalf of the SP702 study group

The presentation will report on the long-term efficacy and tolerability of rotigotine in early stage Parkinson's disease.

Date: Wednesday, April 14, 2010

Poster #: P04.133: Movement Disorders: Parkinson's Disease: Treatment

Authors present: 6:00 PM EDT

Place: Room 808

Citation: Extensive Neupro (R) (rotigotine transdermal system) data to be presented at the 62nd American Academy of Neurology Meet (2010, April 8) retrieved 20 August 2026 from https://sciencex.com/wire-news/32178144/extensive-neupro-r-rotigotine-transdermal-system-data-to-be-pres.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.